

tonolysis of **3** that gives cyclohexanone, **4** reacts with HCl to give  $\text{Cp}_2\text{ZrCl}_2$  and cyclohexene (GC/MS;  $^1\text{H}$  NMR), demonstrating that the O-atom has not been transferred to a Zr-C bond in this complex.

**Acknowledgment.** Financial support from the National Science Foundation (Grant CHE-8520329) and the donors of the Petroleum Research Fund, administered by the American Chemical Society (17718-AC3), is appreciated by G.L.H. Support from the National Institutes of Health (GM 34917), the Camille and Henry Dreyfus Fund, the American Cancer Society (for a Junior Faculty Research Award), and Firmenich SA is gratefully acknowledged by S.L.B. The NMR facilities were supported in part through the University of Chicago Cancer Center Grant (NIH-CA-14599).

**Supplementary Material Available:** Experimental details and tables of atomic coordinates, bond angles and distances, anisotropic thermal parameters, and hydrogen atom coordinates (9 pages); table of observed and calculated structure factors (13 pages). Ordering information is given on any current masthead page.


## Synthesis of (-)-Oxetanocin

Daniel W. Norbeck\* and James B. Kramer

*Anti-infective Research Division  
Abbott Laboratories, Abbott Park, Illinois 60064*

Received May 16, 1988

Oxetanocin inhibits the in vitro replication of human immunodeficiency virus (HIV), the causative agent of AIDS.<sup>1,2</sup> X-ray crystallographic analysis<sup>3</sup> of material produced by a strain of *Bacillus megaterium*<sup>4</sup> has established oxetanocin's structure as compound **1**. This unprecedented oxetanosyl-*N*-glycoside presents



new challenges in the synthesis of nucleosides<sup>5</sup> and branched chain carbohydrates.<sup>6</sup> These difficulties are evident in the 19-step Nippon Kayaku synthesis,<sup>7,8</sup> which produces oxetanocin in an overall yield of 0.008%. We report here an alternative synthesis of oxetanocin which should supply sufficient material for the elaboration and biological testing of derivatives.

(1) Hoshino, H.; Shimizu, N.; Shimada, N.; Takita, T.; Takeuchi, T. *J. Antibiot.* **1987**, *40*, 1077-1078.

(2) *AIDS: Modern Concepts and Therapeutic Challenges*; Broder, S., Ed.; Marcel Dekker: New York, 1987.

(3) Nakamura, H.; Hasegawa, S.; Shimada, N.; Fujii, A.; Takita, T.; Yoichi, I. *J. Antibiot.* **1986**, *39*, 1626-1629.

(4) Shimada, N.; Hasegawa, S.; Harada, T.; Tomisawa, T.; Fujii, A.; Takita, T. *J. Antibiot.* **1986**, *39*, 1623-1625.


(5) Walker, R. T. In *Comprehensive Organic Chemistry*; Barton, D., Ollis, W. D., Eds.; Pergamon: New York, 1979; Vol. 5, Chapter 22.2, pp 53-104.

(6) Yoshimura, J. *Adv. Carbohydr. Chem. Biochem.* **1984**, *42*, 69-134.

(7) (a) Niitsuma, S.; Ichikawa, Y.; Kato, K.; Takita, T. *Tetrahedron Lett.* **1987**, 3967-3970. (b) Niitsuma, S.; Ichikawa, Y.; Kato, K.; Takita, T. *Tetrahedron Lett.* **1987**, 4713-4714.

(8) For a recent synthesis of chiral oxetanes, see: (a) Austin, G. N.; Fleet, G. W. J.; Peach, J. M.; Prout, K.; Son, J. C. *Tetrahedron Lett.* **1987**, 4741-4744. (b) Kawahata, Y.; Takatsuto, S.; Ikekawa, N.; Murata, M.; Omura, S. *Chem. Pharm. Bull.* **1986**, *34*, 3102-3110.

## Scheme I. Synthesis of (-)-Oxetanocin<sup>a</sup>



<sup>a</sup> (a) 2-Acetoxyisobutyryl bromide,  $\text{CH}_3\text{CN}$ ; (b) resin<sup>+</sup> $\text{OH}^-$ , MeOH; (c) TBSCl,  $\text{C}_6\text{H}_5\text{N}$ ; (d)  $\text{LiEt}_3\text{BH}$ , THF; (e)  $\text{BzCl}$ ,  $\text{C}_6\text{H}_5\text{N}$ ; (f) 1 N aqueous NaOH, 1,4-dioxane; (g)  $\text{CH}_3\text{CH}_2\text{NCN}(\text{CH}_2)_3\text{N}(\text{CH}_3)_2\text{HCl}$ ,  $\text{Cl}_2\text{CHCO}_2\text{H}$ , DMSO,  $\text{C}_6\text{H}_6$ ; (h)  $(\text{CH}_3\text{O})_2\text{CHN}(\text{CH}_3)_2$ ; (i)  $\text{CF}_3\text{SO}_2\text{N}_3$ ; (j)  $h\nu$ , >280 nm, MeOH; (k)  $\text{NaBH}_4$ , EtOH; (l) TMSCl, MeOH.

Recognition of oxetanocin as a structural isomer of cordycepin (**2**)<sup>9,10</sup> suggested ring contraction as the pivotal synthetic transformation.

Although treatment of cordycepin with *tert*-butyldimethylsilyl chloride<sup>11</sup> in pyridine provided the nucleoside **5** directly, a more economical route utilized (-)-adenosine as the starting material. Thus, addition of 4.0 equiv of  $\alpha$ -acetoxyisobutyryl bromide to a suspension of (-)-adenosine in acetonitrile containing 1.1 equiv of  $\text{H}_2\text{O}$  at room temperature followed by treatment of the ethyl acetate extract with BioRad AG-1-X8 ( $\text{OH}^-$ ) resin in methanol afforded a 92% yield of crystalline 2',3'-anhydroadenosine (**4**) in the manner described by Robins.<sup>12</sup> Silylation of the 5'-hydroxyl group prior to reduction of the epoxide<sup>13</sup> with 4.0 equiv of  $\text{LiEt}_3\text{BH}$  in THF at room temperature facilitated isolation of the required 3'-deoxynucleoside **5** in an overall yield of 85%. The corresponding 2'-deoxynucleoside was not detected. Treatment of compound **5** with 4.0 equiv of benzoyl chloride in pyridine for 3 h at room temperature gave a mixture of di- and tribenzoates, which, without purification, was selectively O-deacylated by aqueous 1 N NaOH in dioxane.<sup>14</sup> Moffatt oxidation<sup>15</sup> of the resulting *N*-protected alcohol was carried out in 1 h by adding 0.2 equiv of dichloroacetic acid every 15 min to 5.0 equiv of 1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide hydrochloride dissolved in a 1:1 mixture of DMSO and benzene. After dilution with dichloromethane, the excess carbodiimide was easily removed by washing with water acidified to pH 3. Chromatography of the organic residue on silica gel with ethyl acetate/hexane afforded the ketone **6** in 63% overall yield from the alcohol **5**.

(9) Cordycepin is the first reported nucleoside antibiotic and is commercially available. *The Merck Index*, 10th ed., Windholz, M., Ed.; Merck: Rahway, NJ, 1983; pp 360-361.

(10) 2'-Deoxyadenosine is, of course, also structurally isomeric. However, 3'-ketonucleosides analogous to **6** readily depurinate. Hansske, F.; Madej, D.; Robins, M. J. *Tetrahedron* **1984**, 125-135.

(11) Corey, E. J.; Venkateswarlu, A. *J. Am. Chem. Soc.* **1972**, *94*, 6190-6191.

(12) Robins, M. J.; Hansske, F.; Low, N. H.; Park, J. I. *Tetrahedron Lett.* **1984**, 367-370.

(13) (a) Hansske, F.; Robins, M. J. *Tetrahedron Lett.* **1985**, 4295-4298. (b) Bazin, H.; Chattopadhyaya, J. *Synthesis* **1985**, 1108-1110.

(14) Köster, H.; Kulikowski, K.; Liese, T.; Heikens, W.; Kohli, V. *Tetrahedron* **1981**, 363-369.

(15) Pfitzer, K. E.; Moffatt, J. G. *J. Am. Chem. Soc.* **1963**, *85*, 3027-3028.

Rapid, base-catalyzed epimerization at C-1'<sup>16</sup> precluded application of the standard formylation-diazo transfer protocol<sup>17,18</sup> to the preparation of diazoketone **8**. However, activation of the 3'-carbon was readily achieved by heating the ketone **6** in neat *N,N*-dimethylformamide dimethyl acetal at 60 °C for 15 min to give the enamino ketone **7** in 80% yield. The observation of NOE's<sup>19</sup> between H-1' and H-4' and H-5' and H-8 verified that the stereochemistry at C-1' had been preserved in this unusually facile reaction.<sup>20</sup> In contrast, diazo transfer<sup>21a</sup> to the enamine<sup>21b</sup> proved to be unusually difficult. After the enamine failed to react with excess tosyl azide in refluxing toluene, we were delighted to find that diazo transfer from triflyl azide<sup>22</sup> in 1,2-dichloroethane at 60 °C was complete in just 2 h. Application of the reaction mixture to a column of silica gel packed in ethyl acetate/hexane and elution with the same solvents (1:3 to 10:0) yielded the diazoketone **8** as a light yellow solid. Salient spectral features of this compound included a strong IR absorption at 2115 cm<sup>-1</sup> (C=N<sup>+</sup>=N<sup>-</sup>), a doublet of doublets ( $J = 7.5$  Hz,  $J' = 5.0$  Hz) at 5.44 ppm assigned to the 4' hydrogen, and an (M + H)<sup>+</sup> = 494.1971 (calcd mass for C<sub>23</sub>H<sub>28</sub>N<sub>7</sub>O<sub>2</sub>Si = 494.1972). In the key step, irradiation of the diazoketone **8** in methanol with a 450-W, Pyrex-filtered, Hanovia lamp for 30 min at room temperature produced the oxetanes **9α** and **9β**, the products of Wolff rearrangement.<sup>23-25</sup> Separation of the diastereomeric oxetanes from each other and from the ketone **6** (12%)<sup>26</sup> and *N*<sup>6</sup>-benzoyladenine (25%)<sup>27</sup> was achieved by chromatography on silica gel. NOE's between the 2' and 5' and 2' and 8 protons established that the major diastereomer (**9α**, 24%,  $[\alpha]^{25}_D -18.4^\circ$  (*c* 1.58, CHCl<sub>3</sub>)) possessed the all-trans stereochemistry of oxetanocin. The absence of these NOE's in the minor, all-cis diastereomer (**9β**, 12%,  $[\alpha]^{25}_D +27.6^\circ$  (*c* 1.01, CHCl<sub>3</sub>)) and the presence of an NOE between the 8 and 5' protons confirmed that the Wolff rearrangement had proceeded with complete retention of configuration.<sup>28</sup> Treatment

of the major epimer with excess NaBH<sub>4</sub> in ethanol rapidly reduced the methyl ester and then, more slowly, effected *N*-debenzoylation to give the monoprotected alcohol **10** (74%), a valuable intermediate for further modification.<sup>29</sup> Addition of 1.7 equiv of trimethylsilyl chloride to a solution of **10** in methanol followed by neutralization with Dowex-SBR (OH<sup>-</sup>) resin released oxetanocin (**1**) in nearly quantitative yield. The identity of the synthetic ( $[\alpha]^{25}_D -41.3^\circ$  (*c* 0.65, pyridine)) and natural ( $[\alpha]^{20}_D -44.3^\circ$  (*c* 0.21, pyridine))<sup>4</sup> material was established by direct comparison (TLC, MS, 300 MHz NMR) with an authentic sample. In particular, the chemical shifts of their ten <sup>13</sup>C NMR (125.8 MHz) resonances in D<sub>2</sub>O differed by less than ±0.03 ppm. In summary, (-)-oxetanocin has been synthesized in 12 steps from adenosine in an overall yield of 5%. Application of this methodology to the preparation of pyrimidine analogues of oxetanocin is in progress.

**Acknowledgment.** We are grateful to Randal Chen for providing a sample of natural oxetanocin and Patricia Pavlik and David Whittern for assistance in obtaining spectral data.

**Supplementary Material Available:** Spectral and physical data for compounds **1** and **5-10** (3 pages). Ordering information is given on any current masthead page.

- (28) (a) Lane, J. F.; Wallis, E. S. *J. Am. Chem. Soc.* **1941**, *63*, 1674-1676. (b) Sax, K. J.; Bergmann, W. *J. Am. Chem. Soc.* **1955**, *77*, 1910-1911. (c) Wiberg, K. B.; Hutton, T. W. *J. Am. Chem. Soc.* **1956**, *78*, 1640-1645. (29) Oxetanocin's purine ring has been modified with a combination of biological and chemical transformations. Shimada, N.; Hasegawa, S.; Saito, S.; Nishikiori, T.; Fujii, A.; Takita, T. *J. Antibiot.* **1987**, *40*, 1788-1790.

## The Structure of 1,4-Cyclohexadiene at 153 K

George A. Jeffrey\*

Department of Crystallography, University of Pittsburgh  
Pittsburgh, Pennsylvania 15260

Jürgen Buschmann, Christian W. Lehmann, and Peter Luger

The Institut für Kristallographie, Freie Universität Berlin  
D-1000 Berlin 33, Federal Republic of Germany  
Received February 8, 1988

The minimum energy conformation of 1,4-cyclohexadiene (1,4-dihydrobenzene)<sup>1-8</sup> has become a subject of renewed interest because of recent research on the structure of its cis and trans substituted and condensed ring derivatives.<sup>9-14</sup>

There are conflicting conclusions concerning the structure of the parent molecule in the gas phase. One electron diffraction study concluded that the molecule was planar or nearly planar,<sup>3</sup> but a later study<sup>6</sup> favored a nonplanar molecule with C<sub>2h</sub> symmetry and a dihedral angle of 159° between the ethylene planes. The boat conformation was apparently favored,<sup>9</sup> although the vibration, rotational Raman, and NMR spectra were best interpreted as

- (1) Gerding, H.; Haak, F. A. *Recl. Trav. Chem. Pays.-Bas.* **1949**, *68*, 293-300. (2) Monostori, B. J.; Weber, A. *J. Mol. Spectrosc.* **1964**, *12*, 129-145. (3) Dallinga, G.; Toneman, L. H. *J. Mol. Struct.* **1967**, *1*, 11-23. (4) Stidham, H. D. *Spectrochim. Acta* **1965**, *21*, 23-32. (5) Garbach, E. W., Jr.; Griffith, M. G. *J. Am. Chem. Soc.* **1968**, *90*, 3590-3592. (6) Oberhammer, H.; Bauer, S. H. *J. Am. Chem. Soc.* **1969**, *91*, 10-16. (7) Laene, J.; Lord, R. C. *J. Mol. Spectrosc.* **1971**, *39*, 340-344. (8) Allinger, N. L.; Sprague, J. T. *J. Am. Chem. Soc.* **1972**, *94*, 5734-5747. (9) Rabideau, P. W. *Acc. Chem. Res.* **1978**, *11*, 141-147. (10) Grossel, M. C. *Tetrahedron Letters* **1980**, *21*, 1075-1078. (11) Grossel, M. C.; Cheetham, A. K.; James, D.; Newsam, J. M. *J. Chem. Soc., Perkin Trans. 2* **1980**, 471-475. (12) Cheetham, A. K.; Gossel, M. C.; Newsam, J. M. *J. Am. Chem. Soc.* **1981**, *103*, 5363-5372. (13) Cheetham, A. K.; Gossel, M. C.; James, D. *J. Org. Chem.* **1982**, *566-568*. (14) Rabideau, P. W.; Lipkowitz, K. B.; Nachbar, R. B., Jr. *J. Am. Chem. Soc.* **1984**, *106*, 3119-3123.

(16) See, for instance: Kawana, M.; Takeuchi, K.; Ohba, T.; Kuzuhara, H. *Nucleic Acids Research Symposium Series No. 17* **1986**, 37-40.

(17) *Diazo Compounds: Properties and Synthesis*; Regitz, M., Maas, G., Eds.; Academic: Orlando, 1987.

(18) Taber, D. F.; Ruckle, R. E.; Hennessy, M. J. *J. Org. Chem.* **1986**, *51*, 4077-4078.

(19) The nuclear Overhauser effect (NOE) has been used to study the conformation of purine nucleosides and nucleotides: (a) Schirmer, R. E.; Davis, J. P.; Noggle, J. H.; Hart, P. A. *J. Am. Chem. Soc.* **1972**, *94*, 2561-2572. (b) Gueron, M.; Chachaty, C.; Son, T.-D. *Ann. N.Y. Acad. Sci.* **1973**, *222*, 307-323. The geometry of **7** was deduced from an NOE between H-4' and the CH<sub>3</sub>'s.

(20) Compare: (a) Abdulla, R. F.; Fuhr, K. H. *J. Org. Chem.* **1978**, *43*, 4248-4250. (b) Schuda, P. F.; Ebner, C. B.; Morgan, T. M. *Tetrahedron Lett.* **1986**, 2567-2570. (c) Conrow, R.; Portoghese, P. S. *J. Org. Chem.* **1986**, *51*, 938-940. (d) For a review of amide acetals, see: Abdulla, R. F.; Brinkmeyer, R. S. *Tetrahedron* **1979**, *35*, 1675-1735.

(21) (a) Regitz, M. *Synthesis* **1972**, 351-373. (b) Fusco, R.; Bianchetti, G.; Pocar, D.; Ugo, R. *Chem. Ber.* **1963**, *96*, 802-812.

(22) A ~0.35 M solution of triflyl azide in 1,2-dichloroethane was prepared by the method of Cavender and Shiner (Cavender, C. J.; Shiner, V. J. *J. Org. Chem.* **1972**, *37*, 3567-3569). This solution (80 mL/g of **7**) was washed with aqueous NaHCO<sub>3</sub> just prior to use. Although we have not experienced an explosion, triflyl azide should always be handled behind a safety shield.

(23) For reviews, see: (a) Meier, H.; Zeller, K.-P. *Angew. Chem., Int. Ed. Engl.* **1975**, *14*, 32-43. (b) Redmore, D.; Gutsche, C. D. In *Advances in Alicyclic Chemistry*; Hart, H., Karabatsos, G. J., Eds.; Academic: New York, 1971; pp 125-136. (c) Baron, W. J.; Decamp, M. R.; Hendrick, M. E.; Jones, M.; Levin, R. H.; Sohn, M. B. In *Carbenes*; Jones, M., Moss, R. A., Eds.; Wiley: New York, 1973; Vol. 1, pp 117-125.

(24) Simple oxetanes have been prepared by the photochemical Wolff rearrangement. (a) Korobitsyna, I. K.; Rodina, L. L.; Stashkova, L. M. *Zh. Obshch. Khim.* **1963**, *33*, 3109. (b) Korobitsyna, I. K.; Rodina, L. L. *Zh. Org. Khim.* **1965**, *1*, 932-938.

(25) For a recent mechanistic study of the Wolff rearrangement, see: McMahon, R. J.; Chapman, O. L.; Hayes, R. A.; Hess, T. C.; Krimmer, H. P. *J. Am. Chem. Soc.* **1985**, *107*, 7597-7606.

(26) Hydrogen abstraction from the solvent by the intermediate carbene would regenerate the ketone **6**. (a) Padway, A.; Layton, R. *Tetrahedron Lett.* **1965**, 2167-2170.

(27) *N*-6-Benzoyladenine could arise from isomerization of the 2'-keto-3'-carbene to the 3'-keto-2'-carbene via an oxirene, hydrogen abstraction,<sup>26</sup> and β-elimination.<sup>10</sup> Subsequent elimination of *tert*-butyldimethylsilylanol would account for our inability to detect the resulting sugar moiety by TLC. (a) Pfitzer, K. E.; Moffatt, J. G. *J. Am. Chem. Soc.* **1965**, *87*, 5661-5770. (b) Cook, A. F.; Moffatt, J. G. *J. Am. Chem. Soc.* **1967**, *89*, 2697-2705.